{
    "2019-04-30": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Financial Exchange Stock Talk: Dividend Sensei On AbbVie",
                "features": {
                    "keywords": [
                        "Dividend",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Top Stock Reports for Facebook, Comcast & AbbVie",
                "features": {
                    "keywords": [
                        "Stock",
                        "Reports",
                        "Facebook",
                        "Comcast",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "media",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Neurocrine Biosciences Has Robust Late-Stage Pipeline",
                "features": {
                    "keywords": [
                        "Neurocrine",
                        "Biosciences",
                        "Pipeline"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-12",
                "original_text": "European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis",
                "features": {
                    "keywords": [
                        "European",
                        "Commission",
                        "SKYRIZI",
                        "risankizumab",
                        "Psoriasis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-07-30",
                "original_text": "AbbVie’s Guidance for Second Quarter of Fiscal 2019",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Guidance",
                        "Second",
                        "Quarter",
                        "Fiscal",
                        "2019"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-27",
                "original_text": "AbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Parkinson's",
                        "Disease",
                        "Multiple",
                        "Sclerosis",
                        "American",
                        "Academy",
                        "Neurology"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}